Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AN 113111; GE 145

Latest Information Update: 25 May 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GE Healthcare
  • Developer Daiichi Sankyo Company; GE Healthcare
  • Class Amides; Aza compounds; Contrast media; Diagnostic agents; Imaging agents; Iodobenzenes; Small molecules
  • Mechanism of Action Tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Vascular disorders

Most Recent Events

  • 01 Dec 2012 GE Healthcare completes a phase II trial in Vascular disorders (diagnosis, in the elderly) in USA (NCT01252810)
  • 01 Aug 2012 GE Healthcare completes a phase I/II trial in Vascular disorders (healthy volunteers) in USA (NCT01672996)
  • 07 Jul 2012 GE Healthcare initiates enrolment in a phase I/II trial in Diagnostic imaging (in healthy volunteers) in USA (NCT01672996)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top